Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
批准号:
10586461
负责人:
Jeffrey C. Rathmell
金额:
$40.73万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-04-01 至 2027-01-31
关键词:
Amino AcidsApoptosisAutoimmune DiseasesBiological AssayCD4 Positive T LymphocytesCRISPR screenCarbonCell physiologyCellsCellular Metabolic ProcessCellular biologyDNA MethylationDataDependenceDietDiseaseDisease modelEnzymesEquilibriumEragrostisFOXP3 geneFeverFolic AcidFolic Acid AntagonistsFolic Acid DeficiencyFormatesFormyltetrahydrofolatesGeneticGlucoseGoalsGuide RNAHumanIL17 geneImageImmuneImmunityImmunologicsImpairmentInflammationInflammatoryInflammatory Bowel DiseasesInterferon Type IIInterruptionLibrariesMeasuresMetabolicMetabolic PathwayMetabolismMethionineMethodsMethotrexateMitochondriaMusNucleotidesNutrientNutrient availabilityOxidoreductasePathway interactionsPatternPharmaceutical PreparationsPlayPositron-Emission TomographyProductionPurinesReactive Oxygen SpeciesRegulationRegulatory PathwayRegulatory T-LymphocyteRoleShapesSignal TransductionSiteT cell differentiationT cell regulationT-Cell ActivationT-Cell ProliferationT-LymphocyteT-Lymphocyte SubsetsTemperatureTestingTh1 CellsTherapeuticTissuesTracerWorkconditional knockoutcytokinedeprivationdietaryeffector T cellglucose uptakehistone methylationin vivometabolomicsmicrobiotanucleotide metabolismprogramsrecruitresponseuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
Inflammatory diseases are often driven by inappropriate responses of effector CD4 T cells (Teff). IL17, IFNγ, or
dual-producing polyfunctional effector Th1, Th17, or Th17.1 T cells can become imbalanced with suppressive
Treg CD4 T cells in a variety of disease settings, including inflammatory bowel diseases (IBD). A key therapeutic
objective in efforts to shift the immunologic balance towards tolerance, therefore, is to selectively inhibit Teff and
promote Treg. We have shown that Teff and Treg subsets utilize different metabolic programs that represent
fundamental features of T cell biology. Here we explore one carbon (1C) metabolism and related
microenvironmental factors to modulate CD4 T cells in inflammatory diseases. 1C metabolism integrates multiple
nutrient inputs to provide intermediates for de novo methionine and purine synthesis and is commonly targeted
with anti-folate drugs. An in vivo CRISPR screen of primary T cells in IBD with a 1C metabolism enzyme-focused
gRNA library identified the mitochondrial enzyme Methylene-tetrahydrofolate Dehydrogenase 2 (MTHFD2) as
conditionally essential for effector T cell proliferation and inflammation. MTHFD2 was upregulated in T cells a
variety of inflammatory conditions and while MTHFD2-deficiency impaired Teff, MTHFD-deficient Treg had
increased FoxP3 expression in both mouse and human T cells. Consistent with a role as a metabolic checkpoint
on inflammation, MTHFD2-deficiency protected against IBD and other inflammatory diseases. Mechanistically,
MTHFD2 inhibition suppressed mTORC1 activity, possibly through reduced methionine and/or interrupted purine
synthesis. Importantly, local nutrients play key roles in 1C metabolism and T cell fate. To quantify T cell access
to nutrients in vivo, we established Positron Emission Tomography (PET) tracer-based methods to directly image
and measure nutrient uptake in vivo. These studies showed a sharp increase in T cell glucose uptake in
inflammation. In addition, IBD is often associated with folate-deficiency. The effects of dietary folate on T cell
1C metabolism, mTORC1 signaling, and fate, however, are unclear. Because inflammation is associated with
fevers and enzymes are temperature-dependent, we also tested fever conditions on T cell metabolism. We found
fever led to increased cytokine production from Teff and mitochondrial Reactive Oxygen Species (ROS)
specifically in Th1 cells that, surprisingly, led to Tp53-dependent apoptosis. These findings support the
hypothesis that 1C metabolism is limiting and serves as a metabolic checkpoint to integrate local nutrients and
physical conditions through MTHFD2 and mTORC1 signaling to provide new immunometabolic targets to
modulate effector and regulatory T cells. To test this, we will: (1) Test the role and mechanism of MTHFD2 as a
limiting enzyme in methionine and nucleotide synthesis essential for mTORC1 signaling and effector T cells; and
(2) Determine how nutrient and microenvironmental factors such as folate and fever influence effector and
regulatory T cell metabolism and inflammation. These studies will test MTHFD2 and identify new
immunometabolic mechanisms and targets that contribute to or may be exploited to treat inflammatory disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic barriers to T cell activation in clear cell renal cell carcinoma
-
批准号:10532599
-
项目类别:
-
资助金额:$55.33万
-
财政年份:2018
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma
-
批准号:10375526
-
项目类别:
-
资助金额:$43.05万
-
财政年份:2018
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
-
批准号:10380136
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2015
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
-
批准号:9269283
-
项目类别:
-
资助金额:$37.91万
-
财政年份:2015
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
-
批准号:9889950
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2015
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
-
批准号:8890911
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2015
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory disease
-
批准号:9126664
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2015
-
负责人:Jeffrey C. Rathmell
-
依托单位:
B cell metabolism in activation and autoantibody production
-
批准号:8561193
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2013
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose Transport in Regulation of T Cell Activation and Inflammation
-
批准号:8513581
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2012
-
负责人:Jeffrey C. Rathmell
-
依托单位:
T cell metabolism as a determinant of differentiation in allergic asthma
-
批准号:8448682
-
项目类别:
-
资助金额:$36.89万
-
财政年份:2011
-
负责人:Jeffrey C. Rathmell
-
依托单位:
T cell metabolism as a determinant of differentiation in allergic asthma
-
批准号:9096333
-
项目类别:
-
资助金额:$1.57万
-
财政年份:2011
-
负责人:Jeffrey C. Rathmell
-
依托单位:
T cell metabolism as a determinant of differentiation in allergic asthma
-
批准号:8094015
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2011
-
负责人:Jeffrey C. Rathmell
-
依托单位:
T cell metabolism as a determinant of differentiation in allergic asthma
-
批准号:8645712
-
项目类别:
-
资助金额:$36.39万
-
财政年份:2011
-
负责人:Jeffrey C. Rathmell
-
依托单位:
T cell metabolism as a determinant of differentiation in allergic asthma
-
批准号:8255492
-
项目类别:
-
资助金额:$38.76万
-
财政年份:2011
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose metabolism and cell death in cancer
-
批准号:8004097
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2007
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose metabolism and cell death in cancer
-
批准号:7753198
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose metabolism and cell death in cancer
-
批准号:7391722
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose metabolism and cell death in cancer
-
批准号:7259909
-
项目类别:
-
资助金额:$29.62万
-
财政年份:2007
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Glucose metabolism and cell death in cancer
-
批准号:7554136
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Jeffrey C. Rathmell
-
依托单位:
Trophic Regulation in T Cell Homeostasis and Disease
-
批准号:7103776
-
项目类别:
-
资助金额:$38.82万
-
财政年份:2006
-
负责人:Jeffrey C. Rathmell
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: